Radiopharm Theranostics reported revenue of $0.24M and net income of -$0.71M for the quarter ended Jun 2026. This income statement covers 5 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2023 | Jun2024 | Dec2024 | Jun2025 | Jun2026 |
|---|---|---|---|---|---|
| Revenue & cost | |||||
| Revenue | 0.24M | 0.07M | 0.24M | ||
| Cost of RevenueCost of Rev | 0.21M | 3.59M | 0.34M | ||
| Gross Profit | 0.02M | -3.53M | -0.09M | ||
| Operating items | |||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | 0.00M | 0.00M | 0.01M | ||
| Research & DevelopmentR&D | -22.63M | -23.09M | -27.52M | 0.61M | |
| Selling, General & AdministrativeSG&A | -12.23M | -13.04M | -14.64M | ||
| Other Operating ExpensesOther Opex | -2.68M | -8.86M | -4.07M | ||
| Operating ExpensesOpex | -34.86M | 0.29M | -42.15M | 0.62M | |
| Operating IncomeOp. Inc | -34.49M | -47.21M | -38.17M | -0.71M | |
| EBIT | -34.49M | -0.26M | -38.17M | -0.71M | |
| Non-operating items | |||||
| Non Operating Interest Expenses | -0.09M | -0.64M | -0.07M | ||
| Other Non Operating IncomeOther Non Op Inc. | -0.26M | -1.23M | -0.35M | ||
| Net income details | |||||
| EBT | -34.57M | -47.85M | -38.24M | -0.71M | |
| Tax ProvisionsTaxes | -0.04M | -0.10M | -0.10M | ||
| Profit After TaxPAT | -35.34M | -47.75M | -37.88M | -0.71M | |
| Income from Non-Controlling InterestsInc. Minority | -0.16M | -1.96M | -1.64M | ||
| Income from Continuing OperationsIncome (Continuing) | -34.54M | -0.26M | -38.14M | -0.71M | |
| Consolidated Net IncomeConsol Net Inc. | -34.54M | -0.26M | -38.14M | -0.71M | |
| Income towards Parent CompanyParent Net Inc | -34.54M | -0.26M | -38.14M | -0.71M | |
| Net Income towards Common StockholdersNet Income | -34.54M | -0.26M | -38.14M | -0.71M | |
| Additional items | |||||
| EPS (Basic) | -0.11 | 0.00 | -0.02 | 0.00 | |
| EPS (Diluted) | -0.11 | 0.00 | -0.02 | 0.00 | |
| Shares Outstanding | 305.83M | 386.46M | 386.46M | 2,081.06M | 2,081.06M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 305.83M | 386.46M | 386.46M | 2,081.06M | 2,081.06M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 339.31M | 460.37M | 2,364.95M | ||
| EBITDA | -34.49M | -0.26M | -38.17M | -0.71M | |
| Interest ExpensesInt Expense | -0.09M | -0.64M | -0.07M | ||
| Tax Rate | 0.11% | 0.20% | 0.27% |